Account management and coordination around market access stakeholders. Given the complex stakeholders’ map, pharmaceutical ... from all stakeholder-facing functions. Supporting change management ...

and to establish if there was broad uniformity in how market access was defined and developed. There were 104 responders, comprised of 50% from pharma, 41% from agencies and the remainder from ...

Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access ...

Founded in 1935 by Khwaja Abdul Ahmeid, Cipla operates through two segments: Pharmaceuticals and New Ventures. Cipla Limited specialises in developing medications, primarily treating respiratory ...

Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of ...

Adoption of CRM to streamline clinical data coordination globally. Demand for compliance-focused CRM solutions in regulatory-intensive environments. Need for real-time data sharing to accelerate ...

DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical Regulatory Affairs Market Size, Share & Trends ... In addition, in the UK, the launch of The Accelerated Access Collaborative, a government initiative ...

Ahmedabad: Gujarat's pharmaceutical sector is back in the spotlight, ending 2024 on a high note with double-digit growth for the first time in three years. With Rs 9,855 crore in moving annual ...

Sun Pharmaceutical Industries Ltd is set to release its Q3 earnings for the quarter ending December 31, 2024, on Friday, January 31. The board will review and decide on the declaration of an ...

2. Eton Pharmaceuticals (NASDAQ:ETON) Company Profile Year-on-year gain: 195.98 percent Market cap: US$372.89 million Share price: US$14 Eton Pharmaceuticals is developing and commercializing ...

As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion deal for the Chinese biopharma's phase 1 T-cell engager. Later during ...

the industry now looks forward to policies that further align with India’s ambition of becoming a $130B pharma market by 2030. “This year’s expectations revolve around incentivising research ...